Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.

Casper SteenholdtRuben Due LorentsenPernille Nørgaard PetersenElla Sk WidigsonCharlotte KloftRolf Anton KlaasenJørn Brynskov

Published in: Journal of gastroenterology and hepatology (2024)

Our study supports maintaining adequate drug exposure being essential for sustained positive outcomes of vedolizumab and emphasizes individualized, therapeutic drug monitoring-based treatment regimens. Controlled trials and pharmacokinetic modeling are, however, needed.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
emergency department
type diabetes
stem cells
mesenchymal stem cells
insulin resistance
electronic health record